

IN THIS UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0230

Inventors: Mary Jo Mulligan-Kehoe

Serial No.: 10/686,428

Filing Date: October 14, 2003

Examiner: Huynh, Phuong N.

Customer No.: 26259

Group Art Unit: 1644

Confirmation No.: 1865

Title: Methods for Modulating Angiogenesis

"Express Mail" Label No. EV583917499US

Date of Deposit December \_\_, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents Post Office Box 1450, Alexandria, VA 22313-1450

By \_\_\_\_\_  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

( ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

(XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

(XX) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.


Respectfully submitted,

Jane Massey Licata  
Registration No. 32,257

Date: December, 2005

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

<b>Form PTO-1449 Modified</b>		<b>Socket No.</b> DC-0230	<b>Serial No.</b> 10/686,428
<b>List of Patents and Publications Cited by Applicant (Use several sheets if necessary)</b>		<b>Applicant</b> Mary Jo Mulligan-Kehoe	
		<b>Filing Date</b> October 14, 2003	<b>Group</b> 1644
<b>U.S. Department of Commerce</b>			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	FA	Planus et al., "Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading", Journal of Cell Science 1997 110:1091-1098	
	FB	Soff G.A., "Angiostatin and angiostatin-related proteins", Cancer Metastasis Rev. 2000 19(1-2):97-107	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	